- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04872257
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
Combined Therapy With NB-UVB Phototherapy and Oral Vitamin D Supplementation in Patients With Vitiligo: a Randomized-clinical Trial, Triple-blind, Placebo-controlled
Study Overview
Status
Intervention / Treatment
Detailed Description
A randomized clinical trial, triple-blind, placebo-controlled treating patients with diagnosed vitiligo. The intervention group will be treated with oral vitamin D 5,000 IU per day and NB-UVB phototherapy. The control group will be treated with placebo and NB-UVB phototherapy. We will evaluate the efficacy (repigmentation rate) and improvement of the quality of life with vitamin D and phototherapy versus placebo and phototherapy.
Our objectives are:
- Evaluate if the use of the supplementation with oral vitamin D accelerates the repigmentation rate in vitiligo lesions treated with NB-UVB phototherapy, achieving a lower accumulated dose of phototherapy.
- Compare basal blood levels of vitamin D before and after treatment completion.
- Compare quality of life of the intervention group with the control group.
- Associate pigmentation rates between intervention and control group obtained with tools that assess activity of disease, such as, Vitiligo Area and Severity Index (VASI) and Vitiligo European Task Force (VETF) score.
- Compare results in quality of life between intervention and control group obtained with tools, such as, Vitiligo-Specific Quality-of-Life Instrument (VitiQoL) and Dermatology Life Quality Index (DLQI).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nuevo Leon
-
Monterrey, Nuevo Leon, Mexico, 64460
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females, ≥ 18 years of age at the time of signing the informed consent document.
- ≥5% of affected skin area
- Inactive, generalized vitiligo (inactive for a minimum of 6 months). [Inactive: No new spontaneous lesions or a rapid progression of these.]
- Subjects who have not been treated with phototherapy previously.
- Subject who have not been treated with topical corticosteroids for at least 8 weeks or immunomodulators for at least 12 weeks.
Exclusion Criteria:
- Subjects with <5% of affected skin area
- Subjects who use multivitamins, diuretics, lipase-inhibitors (orlistat)
- Subjects with calcium disorders (for example: primary hyperparathyroidism) or patients with hepatic/kidney failure.
- Subjects with malabsorption gastrointestinal disorders
- Pregnant women or in lactation
- Subjects with cancer
- Subjects with previous history of skin cancer (melanoma/non-melanoma)
- Photo-sensible diseases (actinic dermatitis, porphyria, xeroderma pigmentosa) or drugs
- Subjects using immunomodulator o immunosuppressor treatments
- Subjects who practice activities that require prolonged sun exposure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oral Vitamin D + NB-UVB Phototherapy
|
Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions.
Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session.
Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
|
PLACEBO_COMPARATOR: Placebo + NB-UVB Phototherapy
|
NB-UVB Phototherapy twice per week for 6 months until completing 48 sessions.
Initial dose of 200 mJ/cm² with a 10-20% increase to the previous session.
Maximum dose for face and neck is 1500 mJ/cm² and 3000 mJ/cm² for the rest of the body.
Administered orally daily for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VASI score - Vitiligo Area and Severity Index (VASI)
Time Frame: Week 0
|
The VASI score is used to assess the severity and extent of Vitiligo.
VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100).
The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.
|
Week 0
|
VASI score - Vitiligo Area and Severity Index (VASI)
Time Frame: Week 12
|
The VASI score is used to assess the severity and extent of Vitiligo.
VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100).
The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.
|
Week 12
|
VASI score - Vitiligo Area and Severity Index (VASI)
Time Frame: Week 24
|
The VASI score is used to assess the severity and extent of Vitiligo.
VASI is calculated using a formula that includes contributions from all body regions (possible range, 0-100).
The body is divided into 6 separate and mutually exclusive sites (head/neck, hands, upper extremities [excluding hands], trunk, lower extremities [excluding feet], and feet), with percentage of vitiligo involvement estimated in hand units by the same investigator throughout the study.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VETF score - Vitiligo European Task Force (VETF) score
Time Frame: Week 0
|
The VETF is a validated scoring system that assesses 3 dimensions of the disease (extent, staging, and spreading/progression). (1) the extent of vitiligo will be estimated as the percentage of vitiligo involvement of 5 body sites. (2) Stage of vitiligo will be assessed as 0 (normal pigmentation), 1 (incomplete depigmentation), 2 (complete depigmentation), 3 (partial hair whitening [<30%]), and 4 (complete hair whitening). (3) Spreading of vitiligo will be scored as 0 (stable disease), -1 (observed ongoing subclinical repigmentation), and +1 (additional patches in a given area or observed ongoing subclinical depigmentation). The VETF score calculated as follows: VETF Extent or Staging or Spreading = Sum of all specific values for that category from all body sites (% of Area affected for Extent; 0-20 for Staging; -5 to +5 for Spreading). |
Week 0
|
VETF score - Vitiligo European Task Force (VETF) score
Time Frame: Week 12
|
The VETF is a validated scoring system that assesses 3 dimensions of the disease (extent, staging, and spreading/progression). (1) the extent of vitiligo will be estimated as the percentage of vitiligo involvement of 5 body sites. (2) Stage of vitiligo will be assessed as 0 (normal pigmentation), 1 (incomplete depigmentation), 2 (complete depigmentation), 3 (partial hair whitening [<30%]), and 4 (complete hair whitening). (3) Spreading of vitiligo will be scored as 0 (stable disease), -1 (observed ongoing subclinical repigmentation), and +1 (additional patches in a given area or observed ongoing subclinical depigmentation). The VETF score calculated as follows: VETF Extent or Staging or Spreading = Sum of all specific values for that category from all body sites (% of Area affected for Extent; 0-20 for Staging; -5 to +5 for Spreading). |
Week 12
|
VETF score - Vitiligo European Task Force (VETF) score
Time Frame: Week 24
|
The VETF is a validated scoring system that assesses 3 dimensions of the disease (extent, staging, and spreading/progression). (1) the extent of vitiligo will be estimated as the percentage of vitiligo involvement of 5 body sites. (2) Stage of vitiligo will be assessed as 0 (normal pigmentation), 1 (incomplete depigmentation), 2 (complete depigmentation), 3 (partial hair whitening [<30%]), and 4 (complete hair whitening). (3) Spreading of vitiligo will be scored as 0 (stable disease), -1 (observed ongoing subclinical repigmentation), and +1 (additional patches in a given area or observed ongoing subclinical depigmentation). The VETF score calculated as follows: VETF Extent or Staging or Spreading = Sum of all specific values for that category from all body sites (% of Area affected for Extent; 0-20 for Staging; -5 to +5 for Spreading). |
Week 24
|
Vitamin D blood levels
Time Frame: Week 0
|
Measure vitamin D levels on blood between the intervention and control group
|
Week 0
|
Vitamin D blood levels
Time Frame: Week 12
|
Measure vitamin D levels on blood between the intervention and control group
|
Week 12
|
Vitamin D blood levels
Time Frame: Week 24
|
Measure vitamin D levels on blood between the intervention and control group
|
Week 24
|
DLQI - Dermatology Life Quality Index
Time Frame: Week 0
|
The DLQI is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions, and its use has been described in over 1000 publications including many multinational studies.
The DLQI is the most frequently used instrument in studies of randomized controlled trials in dermatology.
|
Week 0
|
DLQI - Dermatology Life Quality Index
Time Frame: Week 24
|
The DLQI is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions, and its use has been described in over 1000 publications including many multinational studies.
The DLQI is the most frequently used instrument in studies of randomized controlled trials in dermatology.
|
Week 24
|
VitiQoL - Vitiligo Specific Quality of Life
Time Frame: Week 0
|
VitiQoL is an instrument specific for vitiligo that consists of 16 items, in which the patient perceives the severity of their disease and how it affects their quality of life.
|
Week 0
|
VitiQoL - Vitiligo Specific Quality of Life
Time Frame: Week 24
|
VitiQoL is an instrument specific for vitiligo that consists of 16 items, in which the patient perceives the severity of their disease and how it affects their quality of life.
|
Week 24
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adrian B Cuellar-Barboza, MD, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DE19-00002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiRecruitingHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on Oral Vitamin D
-
King Edward Medical UniversityCompletedDiabetes Mellitus, Type 2 | Vitamin D Deficiency | Insulin Resistance
-
Indonesia UniversityEnrolling by invitationAcne Vulgaris | Vitamin DIndonesia
-
Srinakharinwirot UniversityCompleted
-
Winthrop University HospitalCompleted
-
Shenzhen Center for Chronic Disease ControlDanone Institute China Diet Nutrition Research and CommunicationCompleted
-
Assiut UniversityUnknown
-
Clalit Health ServicesRambam Health Care CampusCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedVitamin D Deficiency | Asthma-COPD Overlap Syndrome | Cardiac Autonomic ToneBangladesh
-
University of UlsterQueen Margaret University, Nutrition and Biological Sciences, Musselburgh... and other collaboratorsRecruitingMusculoskeletal Diseases | Vitamin D Deficiency | Cognitive Delay, MildUnited Kingdom